Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03703297
Recruitment Status : Recruiting
First Posted : October 11, 2018
Last Update Posted : May 24, 2019
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Condition or disease Intervention/treatment Phase
Small Cell Lung Cancer Drug: Durvalumab Drug: Tremelimumab Other: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 600 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)
Actual Study Start Date : September 27, 2018
Estimated Primary Completion Date : June 1, 2021
Estimated Study Completion Date : December 28, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
Drug Information available for: Durvalumab

Arm Intervention/treatment
Experimental: Durvalumab + Placebo
Durvalumab monotherapy: Durvalumab (1500 mg intravenous [IV]) q4w in combination with placebo saline solution (IV) q4w for up to 4 doses/cycles each, followed by durvalumab 1500 mg q4w. The first durvalumab monotherapy 1500 mg dose q4w will be 4 weeks after the final dose of durvalumab in combination with placebo saline solution.
Drug: Durvalumab
Durvalumab IV (intravenous infusion)
Other Name: MEDI4736

Other: Placebo
Placebo IV (intravenous infusion)

Experimental: Durvalumab + Tremelimumab
Durvalumab in combination with tremelimumab: Durvalumab (1500 mg IV) q4w in combination with tremelimumab (75 mg IV) q4w for up to 4 doses/cycles each, followed by durvalumab 1500 mg q4w. The first durvalumab monotherapy 1500 mg dose q4w will be 4 weeks after the final dose of durvalumab in combination with tremelimumab.
Drug: Durvalumab
Durvalumab IV (intravenous infusion)
Other Name: MEDI4736

Drug: Tremelimumab
Tremelimumab IV (intravenous infusion)

Placebo Comparator: Placebo + Placebo
Placebo: Placebo saline solution (IV) q4w in combination with a second placebo saline solution (IV) q4w for up to 4 doses/cycles each, followed by a single placebo saline solution q4w. The first placebo saline solution monotherapy dose q4w will be 4 weeks after the final dose of the 2 placebo saline solutions in combination.
Other: Placebo
Placebo IV (intravenous infusion)




Primary Outcome Measures :
  1. Progression-free survival (PFS) [ Time Frame: Approximately 5 years ]
  2. Overall Survival (OS) [ Time Frame: Approximately 5 years ]

Secondary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: Approximately 5 years ]
  2. Objective Response Rate (ORR) [ Time Frame: Approximately 5 years ]
  3. Progression-free survival PFS [ Time Frame: Approximately 5 years ]
  4. Progression-free survival at 18 months (PFS18) [ Time Frame: Approximately 5 years ]
  5. Progression-free survival at 24 months (PFS24) [ Time Frame: Approximately 5 years ]
  6. Time to death or distant metastasis (TTDM) [ Time Frame: Approximately 5 years ]
  7. Proportion of patients alive at 24 months (OS24) [ Time Frame: Approximately 5 years ]
  8. Proportion of patients alive at and 36 months (OS36) [ Time Frame: Approximately 5 years ]
  9. Time from randomization to second progression (PFS2) [ Time Frame: Approximately 5 years ]
  10. To assess symptoms and health-related QoL in patients treated withdurvalumab or durvalumab and tremelimumab combination therapy compared to placebo using the EORTC QLQ-C30 v3 [ Time Frame: Approximately 5 years ]
  11. To assess the PK of durvalumab and tremelimumab in blood (peak trough concentration) [ Time Frame: Approximately 5 years ]
  12. Presence of anti-drug antibodies (ADA) for durvalumab and tremelimumab (confirmatory results: positive or negative) [ Time Frame: Approximately 5 years ]
  13. To assess a relationship between a tumor mutational burden (TMB) measured as biomarker presence in tumor and/or blood and Progression-free survival (PFS) with durvalumab and durvalumab and tremelimumab combination therapy [ Time Frame: Approximately 5 years ]
  14. To assess symptoms and health-related QoL in patients treated withdurvalumab or durvalumab and tremelimumab combination therapy compared to placebo using the EORTC QLQ-LC13 [ Time Frame: Approximately 5 years ]
  15. To assess a relationship between a tumor mutational burden (TMB) measured as biomarker presence in tumor and/or blood and Objective Response Rate (ORR) with durvalumab and durvalumab and tremelimumab combination therapy [ Time Frame: Approximately 5 years ]
  16. To assess a relationship between a tumor mutational burden (TMB) measured as biomarker presence in tumor and/or blood and Overall Survival (OS) with durvalumab and durvalumab and tremelimumab combination therapy [ Time Frame: Approximately 5 years ]

Other Outcome Measures:
  1. Adverse Events [ Time Frame: Approximately 5 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Histologically or cytologically documented limited-stage small cell lung cancer (stage I-III).
  2. Received 4 cycles of chemotherapy concurrent with radiotherapy, which must be completed within 1 to 42 days prior to randomization and the first dose of IP. Chemotherapy must contain platinum and IV etoposide. Radiotherapy must be either total 60-66 Gy over 6 weeks for the standard QD regimen or total 45 Gy over 3 weeks for hyperfractionated BD schedules.
  3. PCI may be delivered at the discretion of investigator and local standard of care, and must be conducted after the end of cCRT and completed between 1 to 42 days to first dose of IP.

4 .Have not progressed following definitive concurrent chemoradiation 5 .Life expectancy ≥ 12 weeks at Day 1. 6. ECOG 0 or 1 at enrolment.

Exclusion criteria:

  1. Extensive-stage SCLC
  2. Active or prior documented autoimmune or inflammatory disorders
  3. Uncontrolled intercurrent illness, including but not limited to interstitial lung disease.
  4. Active infection including tuberculosis, HIV, hepatitis B and C
  5. Patients who received sequential chemotherapy and radiotherapy (no overlap of RT with chemotherapy)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03703297


Contacts
Layout table for location contacts
Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com
Contact: AstraZeneca Cancer Study, Local service 1-877-400-4656 AstraZeneca@emergingmed.com

  Show 190 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Study Director: Haiyi Jiang, M.D. AstraZeneca

Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT03703297     History of Changes
Other Study ID Numbers: D933QC00001
First Posted: October 11, 2018    Key Record Dates
Last Update Posted: May 24, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by AstraZeneca:
Small Cell Lung Cancer
SCLC
LS-SCLC
Limited Stage
Carcinoma
Lung Cancer

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Durvalumab
Tremelimumab
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs